

5. EMA Note for guidance on the clinical requirements for locally applied, locally acting products containing known constituents (CPMP/EWP/239/95),1995.
 6. EMA, Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in adults and for use in the treatment of asthma in children and adolescents,2009.
 7. FDA Guidance on Topical Dermatologic Corticosteroids: in vivo bioequivalence, 1995.
-

Revision #4

Created 2025-11-26 11:00:17 UTC by Colin Wang

Updated 2025-11-26 15:15:54 UTC by Colin Wang